United Therapeutics (UTHR) Stock Forecast, Price Target & Predictions
UTHR Stock Forecast
United Therapeutics stock forecast is as follows: an average price target of $312.50 (represents a -7.85% downside from UTHR’s last price of $339.12) and a rating consensus of 'Buy', based on 8 wall street analysts offering a 1-year stock forecast.
UTHR Price Target
The average price target for United Therapeutics (UTHR) is $312.50 based on 1-year price targets from 8 Wall Street analysts in the past 3 months, with a price target range of $575.00 to $215.00. This represents a potential -7.85% downside from UTHR's last price of $339.12.
UTHR Analyst Ratings
According to 8 Wall Street analysts, United Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for UTHR stock is 0 'Strong Buy' (0.00%), 6 'Buy' (75.00%), 2 'Hold' (25.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
United Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 28, 2024 | Hartaj Singh | Oppenheimer | $575.00 | $362.44 | 58.64% | 69.56% |
| Jul 08, 2024 | Ashwani Verma | UBS | $370.00 | $317.18 | 16.65% | 9.11% |
| Jun 12, 2024 | Tiago Fauth | Wells Fargo | $350.00 | $275.76 | 26.92% | 3.21% |
| May 02, 2024 | Hartaj Singh | Oppenheimer | $400.00 | $255.14 | 56.78% | 17.95% |
| Feb 12, 2024 | Chris Shibutani | Goldman Sachs | $215.00 | $214.74 | 0.12% | -36.60% |
| Jan 11, 2023 | - | Argus Research | $300.00 | $263.41 | 13.89% | -11.54% |
| Dec 06, 2022 | - | Morgan Stanley | $330.00 | $276.07 | 19.53% | -2.69% |
| Dec 06, 2022 | - | UBS | $320.00 | $273.72 | 16.91% | -5.64% |
| Dec 05, 2022 | - | Goldman Sachs | $230.00 | $278.55 | -17.43% | -32.18% |
| May 24, 2022 | - | J.P. Morgan | $238.00 | $218.00 | 9.17% | -29.82% |
The latest United Therapeutics stock forecast, released on Aug 28, 2024 by Hartaj Singh from Oppenheimer, set a price target of $575.00, which represents a 58.64% increase from the stock price at the time of the forecast ($362.44), and a 69.56% increase from UTHR last price ($339.12).
United Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 2 | 5 |
| Avg Price Target | $575.00 | $472.50 | $382.00 |
| Last Closing Price | $339.12 | $339.12 | $339.12 |
| Upside/Downside | 69.56% | 39.33% | 12.64% |
In the current month, the average price target of United Therapeutics stock is $575.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 69.56% increase as opposed to United Therapeutics's last price of $339.12. This month's average price target is up 21.69% compared to last quarter, and up 50.52% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 28, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| Aug 20, 2024 | UBS | Underperform | Underperform | Hold |
| Aug 20, 2024 | Wells Fargo | Buy | Buy | Hold |
| Aug 20, 2024 | Wells Fargo | Overweight | Overweight | Hold |
| Jul 25, 2024 | UBS | Underperform | Underperform | Hold |
| Jul 25, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jul 11, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Jul 11, 2024 | Morgan Stanley | Overweight | Equal-Weight | Downgrade |
| Jul 08, 2024 | Wells Fargo | Buy | Buy | Hold |
| Jul 08, 2024 | UBS | Buy | Buy | Hold |
United Therapeutics's last stock rating was published by Oppenheimer on Aug 28, 2024. The company gave UTHR a "Outperform" rating, the same as its previous rate.
United Therapeutics Financial Forecast
United Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $609.40M | - | $506.90M | $491.50M | $516.00M | $466.90M | $461.90M | $415.20M | $444.70M | $446.50M | $379.10M | $384.60M | $380.10M | $362.00M | $356.30M | $311.10M | $401.50M | $373.60M | $362.60M | $389.20M | $370.50M |
| Avg Forecast | $872.40M | $859.30M | $822.80M | $778.60M | $728.31M | $726.96M | $691.87M | $620.31M | $575.01M | $585.82M | $524.18M | $514.37M | $519.21M | $493.21M | $461.06M | $420.06M | $427.59M | $421.45M | $378.56M | $368.95M | $362.04M | $358.46M | $339.98M | $344.33M | $357.77M | $337.60M | $332.15M | $335.43M | $245.96M | $315.26M |
| High Forecast | $902.45M | $888.90M | $851.15M | $805.42M | $753.40M | $773.41M | $715.70M | $641.68M | $610.36M | $603.74M | $542.23M | $532.09M | $537.09M | $510.20M | $486.58M | $443.31M | $451.26M | $444.78M | $399.52M | $389.37M | $382.08M | $378.30M | $358.80M | $363.39M | $377.57M | $356.29M | $350.54M | $354.00M | $295.15M | $378.31M |
| Low Forecast | $815.99M | $803.74M | $769.60M | $728.26M | $681.22M | $682.87M | $647.13M | $580.21M | $538.02M | $561.00M | $490.28M | $481.11M | $485.63M | $461.32M | $432.41M | $393.96M | $401.02M | $395.26M | $355.04M | $346.02M | $339.54M | $336.18M | $318.85M | $322.93M | $335.54M | $316.63M | $311.51M | $314.59M | $196.77M | $252.21M |
| # Analysts | 4 | 3 | 4 | 3 | 5 | 8 | 5 | 4 | 8 | 10 | 9 | 9 | 8 | 8 | 8 | 8 | 9 | 9 | 9 | 9 | 9 | 8 | 8 | 9 | 12 | 7 | 7 | 8 | 16 | 12 |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.04% | - | 0.99% | 0.95% | 1.05% | 1.01% | 1.10% | 0.97% | 1.06% | 1.18% | 1.03% | 1.06% | 1.06% | 1.06% | 1.03% | 0.87% | 1.19% | 1.12% | 1.08% | 1.58% | 1.18% |
United Therapeutics's average Quarter revenue forecast for Dec 23 based on 8 analysts is $575.01M, with a low forecast of $538.02M, and a high forecast of $610.36M. UTHR's average Quarter revenue forecast represents a -5.64% decrease compared to the company's last Quarter revenue of $609.40M (Sep 23).
United Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 3 | 4 | 3 | 5 | 8 | 5 | 4 | 8 | 10 | 9 | 9 | 8 | 8 | 8 | 8 | 9 | 9 | 9 | 9 | 9 | 8 | 8 | 9 | 12 | 7 | 7 | 8 | 16 | 12 |
| EBITDA | - | - | - | - | - | - | - | - | - | $327.00M | - | $319.00M | $191.10M | $334.60M | $169.50M | $327.60M | $157.80M | $221.40M | $233.60M | $49.60M | $-117.50M | $235.70M | $152.10M | $192.20M | $90.80M | $191.30M | $273.00M | $-630.00M | $319.50M | $272.30M |
| Avg Forecast | $320.78M | $315.96M | $302.54M | $286.29M | $267.80M | $267.30M | $254.40M | $106.50M | $211.43M | $215.40M | $192.74M | $96.82M | $190.91M | $239.93M | $169.53M | $88.02M | $157.22M | $154.96M | $139.19M | $80.02M | $133.12M | $131.80M | $125.01M | $166.34M | $131.55M | $124.13M | $122.13M | $-3.44B | $146.77M | $224.59M |
| High Forecast | $331.83M | $326.84M | $312.96M | $296.15M | $277.02M | $284.38M | $263.16M | $127.80M | $224.43M | $221.99M | $199.38M | $116.19M | $197.49M | $287.91M | $178.91M | $105.62M | $165.93M | $163.54M | $146.90M | $96.02M | $140.49M | $139.10M | $131.93M | $199.61M | $138.83M | $131.01M | $128.89M | $-2.75B | $176.12M | $269.50M |
| Low Forecast | $300.03M | $295.53M | $282.98M | $267.77M | $250.48M | $251.09M | $237.95M | $85.20M | $197.82M | $206.28M | $180.27M | $77.46M | $178.56M | $191.94M | $158.99M | $70.42M | $147.45M | $145.33M | $130.54M | $64.01M | $124.85M | $123.61M | $117.24M | $133.07M | $123.37M | $116.42M | $114.54M | $-4.13B | $117.42M | $179.67M |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.52% | - | 3.29% | 1.00% | 1.39% | 1.00% | 3.72% | 1.00% | 1.43% | 1.68% | 0.62% | -0.88% | 1.79% | 1.22% | 1.16% | 0.69% | 1.54% | 2.24% | 0.18% | 2.18% | 1.21% |
8 analysts predict UTHR's average Quarter EBITDA for Dec 23 to be $211.43M, with a high of $224.43M and a low of $197.82M. This is -35.34% lower than United Therapeutics's previous annual EBITDA (Sep 23) of $327.00M.
United Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 3 | 4 | 3 | 5 | 8 | 5 | 4 | 8 | 10 | 9 | 9 | 8 | 8 | 8 | 8 | 9 | 9 | 9 | 9 | 9 | 8 | 8 | 9 | 12 | 7 | 7 | 8 | 16 | 12 |
| Net Income | - | - | - | - | - | - | - | - | - | $267.60M | - | $240.90M | $132.10M | $239.30M | $116.00M | $239.90M | $112.20M | $162.70M | $172.60M | $28.30M | $98.00M | $171.20M | $107.10M | $137.70M | $52.60M | $132.40M | $205.10M | $-494.60M | $244.50M | $178.60M |
| Avg Forecast | $437.00M | $434.63M | $417.05M | $414.20M | $316.99M | $313.51M | $308.03M | $60.77M | $203.51M | $242.34M | $217.03M | $55.24M | $224.31M | $176.31M | $208.49M | $50.22M | $170.05M | $170.64M | $143.45M | $45.66M | $140.18M | $134.96M | $131.71M | $119.17M | $125.45M | $120.65M | $117.74M | $-2.70B | $112.32M | $147.30M |
| High Forecast | $456.57M | $454.09M | $435.73M | $432.75M | $331.19M | $367.00M | $321.82M | $72.92M | $257.51M | $270.49M | $226.74M | $66.29M | $234.36M | $211.58M | $223.49M | $60.27M | $182.29M | $182.92M | $153.77M | $54.79M | $150.27M | $144.67M | $141.19M | $143.01M | $134.48M | $129.33M | $126.21M | $-2.16B | $134.78M | $176.77M |
| Low Forecast | $400.27M | $398.09M | $381.99M | $379.38M | $290.35M | $267.94M | $282.14M | $48.61M | $154.19M | $191.30M | $198.78M | $44.19M | $205.46M | $141.05M | $191.65M | $40.18M | $156.31M | $156.86M | $131.86M | $36.52M | $128.86M | $124.06M | $121.07M | $95.34M | $115.32M | $110.90M | $108.23M | $-3.24B | $89.85M | $117.84M |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.10% | - | 4.36% | 0.59% | 1.36% | 0.56% | 4.78% | 0.66% | 0.95% | 1.20% | 0.62% | 0.70% | 1.27% | 0.81% | 1.16% | 0.42% | 1.10% | 1.74% | 0.18% | 2.18% | 1.21% |
United Therapeutics's average Quarter net income forecast for Dec 23 is $203.51M, with a range of $154.19M to $257.51M. UTHR's average Quarter net income forecast represents a -23.95% decrease compared to the company's last Quarter net income of $267.60M (Sep 23).
United Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 3 | 4 | 3 | 5 | 8 | 5 | 4 | 8 | 10 | 9 | 9 | 8 | 8 | 8 | 8 | 9 | 9 | 9 | 9 | 9 | 8 | 8 | 9 | 12 | 7 | 7 | 8 | 16 | 12 |
| SG&A | - | - | - | - | - | - | - | - | - | $127.60M | - | $87.30M | $166.10M | $98.40M | $141.50M | $79.00M | $127.90M | $109.10M | $112.80M | $117.20M | $103.80M | $66.30M | $105.90M | $93.00M | $105.20M | $99.40M | $39.60M | $92.00M | $-6.60M | $56.40M |
| Avg Forecast | $218.34M | $215.07M | $205.93M | $194.87M | $182.28M | $181.94M | $173.16M | $251.66M | $143.91M | $146.62M | $131.19M | $228.78M | $129.95M | $118.23M | $115.39M | $207.98M | $107.02M | $105.48M | $94.75M | $189.07M | $90.61M | $89.72M | $85.09M | $80.49M | $89.54M | $84.50M | $83.13M | $83.95M | $-3.03M | $46.52M |
| High Forecast | $225.87M | $222.47M | $213.02M | $201.58M | $188.56M | $193.57M | $179.13M | $301.99M | $152.76M | $151.10M | $135.71M | $274.54M | $134.42M | $141.88M | $121.78M | $249.58M | $112.94M | $111.32M | $99.99M | $226.89M | $95.63M | $94.68M | $89.80M | $96.58M | $94.50M | $89.17M | $87.73M | $88.60M | $-2.43M | $55.82M |
| Low Forecast | $204.23M | $201.16M | $192.61M | $182.27M | $170.50M | $170.91M | $161.96M | $201.33M | $134.65M | $140.41M | $122.71M | $183.02M | $121.54M | $94.58M | $108.22M | $166.39M | $100.37M | $98.93M | $88.86M | $151.26M | $84.98M | $84.14M | $79.80M | $64.39M | $83.98M | $79.24M | $77.96M | $78.73M | $-3.64M | $37.21M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.87% | - | 0.38% | 1.28% | 0.83% | 1.23% | 0.38% | 1.20% | 1.03% | 1.19% | 0.62% | 1.15% | 0.74% | 1.24% | 1.16% | 1.17% | 1.18% | 0.48% | 1.10% | 2.18% | 1.21% |
United Therapeutics's average Quarter SG&A projection for Dec 23 is $143.91M, based on 8 Wall Street analysts, with a range of $134.65M to $152.76M. The forecast indicates a 12.78% rise compared to UTHR last annual SG&A of $127.60M (Sep 23).
United Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 3 | 4 | 3 | 5 | 8 | 5 | 4 | 8 | 10 | 9 | 9 | 8 | 8 | 8 | 8 | 9 | 9 | 9 | 9 | 9 | 8 | 8 | 9 | 12 | 7 | 7 | 8 | 16 | 12 |
| EPS | - | - | - | - | - | - | - | - | - | $5.71 | - | $5.20 | $2.88 | $5.26 | $2.56 | $5.31 | $2.49 | $3.62 | $3.85 | $0.63 | $2.22 | $3.86 | $2.43 | $3.14 | $1.20 | $3.02 | $4.68 | $-11.32 | $5.65 | $4.01 |
| Avg Forecast | $9.20 | $9.15 | $8.78 | $8.72 | $6.67 | $6.60 | $6.48 | $5.71 | $4.28 | $5.10 | $4.57 | $4.59 | $4.72 | $3.91 | $4.39 | $3.65 | $3.58 | $3.59 | $3.02 | $3.03 | $2.95 | $2.84 | $2.77 | $2.74 | $2.64 | $2.54 | $2.48 | $2.72 | $1.62 | $2.73 |
| High Forecast | $9.61 | $9.56 | $9.17 | $9.11 | $6.97 | $7.73 | $6.78 | $5.96 | $5.42 | $5.69 | $4.77 | $4.79 | $4.93 | $4.08 | $4.71 | $3.91 | $3.84 | $3.85 | $3.24 | $3.25 | $3.16 | $3.05 | $2.97 | $2.94 | $2.83 | $2.72 | $2.66 | $2.91 | $1.94 | $3.28 |
| Low Forecast | $8.43 | $8.38 | $8.04 | $7.99 | $6.11 | $5.64 | $5.94 | $5.23 | $3.25 | $4.03 | $4.18 | $4.20 | $4.33 | $3.58 | $4.03 | $3.35 | $3.29 | $3.30 | $2.78 | $2.79 | $2.71 | $2.61 | $2.55 | $2.52 | $2.43 | $2.33 | $2.28 | $2.50 | $1.29 | $2.18 |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.12% | - | 1.13% | 0.61% | 1.35% | 0.58% | 1.46% | 0.70% | 1.01% | 1.27% | 0.21% | 0.75% | 1.36% | 0.88% | 1.15% | 0.45% | 1.19% | 1.89% | -4.17% | 3.49% | 1.47% |
According to 8 Wall Street analysts, United Therapeutics's projected average Quarter EPS for Dec 23 is $4.28, with a low estimate of $3.25 and a high estimate of $5.42. This represents a -24.97% decrease compared to UTHR previous annual EPS of $5.71 (Sep 23).
United Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| VTYX | Ventyx Biosciences | $2.29 | $33.86 | 1378.60% | Buy |
| DAWN | Day One Biopharmaceuticals | $14.13 | $38.80 | 174.59% | Buy |
| REPL | Replimune Group | $11.13 | $24.20 | 117.43% | Buy |
| APLS | Apellis Pharmaceuticals | $37.62 | $75.81 | 101.52% | Buy |
| LRMR | Larimar Therapeutics | $7.20 | $14.50 | 101.39% | Buy |
| RARE | Ultragenyx Pharmaceutical | $58.74 | $108.14 | 84.10% | Buy |
| MNKD | MannKind | $6.27 | $11.00 | 75.44% | Buy |
| AKRO | Akero Therapeutics | $27.34 | $43.50 | 59.11% | Buy |
| LEGN | Legend Biotech | $50.31 | $78.78 | 56.59% | Buy |
| KNSA | Kiniksa Pharmaceuticals | $25.26 | $37.00 | 46.48% | Buy |
| ASND | Ascendis Pharma | $119.22 | $174.46 | 46.33% | Buy |
| INCY | Incyte | $63.56 | $81.00 | 27.44% | Buy |
| BGNE | BeiGene | $198.49 | $247.75 | 24.82% | Buy |
| NUVL | Nuvalent | $87.45 | $107.33 | 22.73% | Buy |
| BPMC | Blueprint Medicines | $88.90 | $101.50 | 14.17% | Buy |
| PCVX | Vaxcyte | $116.00 | $124.14 | 7.02% | Buy |
| ALNY | Alnylam Pharmaceuticals | $265.27 | $250.16 | -5.70% | Buy |
| UTHR | United Therapeutics | $339.12 | $312.50 | -7.85% | Buy |
UTHR Forecast FAQ
Is United Therapeutics a good buy?
Yes, according to 8 Wall Street analysts, United Therapeutics (UTHR) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 6 'Buy' recommendations, accounting for 75.00% of UTHR's total ratings.
What is UTHR's price target?
United Therapeutics (UTHR) average price target is $312.5 with a range of $215 to $575, implying a -7.85% from its last price of $339.12. The data is based on 8 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will United Therapeutics stock go up soon?
According to Wall Street analysts' prediction for UTHR stock, the company can go down by -7.85% (from the last price of $339.12 to the average price target of $312.5), up by 69.56% based on the highest stock price target, and down by -36.60% based on the lowest stock price target.
Can United Therapeutics stock reach $500?
UTHR's highest twelve months analyst stock price target of $575 supports the claim that United Therapeutics can reach $500 in the near future.
What is United Therapeutics's current price target trend?
1 Wall Street analyst forecast a $575 price target for United Therapeutics (UTHR) this month, up 69.56% from its last price of $339.12. Compared to the last 3 and 12 months, the average price target increased by 39.33% and increased by 12.64%, respectively.
What are United Therapeutics's analysts' financial forecasts?
United Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $2.77B (high $2.88B, low $2.59B), average EBITDA is $895.99M (high $952.36M, low $824.72M), average net income is $999.29M (high $1.09B, low $889.04M), average SG&A $789.04M (high $863.25M, low $704.7M), and average EPS is $25.46 (high $27.44, low $22.92). UTHR's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $3.33B (high $3.45B, low $3.12B), average EBITDA is $1.23B (high $1.27B, low $1.15B), average net income is $1.7B (high $1.78B, low $1.56B), average SG&A $834.21M (high $862.95M, low $780.27M), and average EPS is $35.85 (high $37.46, low $32.84).
Did the UTHR's actual financial results beat the analysts' financial forecasts?
Based on United Therapeutics's last annual report (Dec 2022), the company's revenue was $1.94B, beating the average analysts forecast of $1.89B by 2.26%. Apple's EBITDA was $984.7M, beating the average prediction of $688.38M by 43.05%. The company's net income was $727.3M, beating the average estimation of $659.34M by 10.31%. Apple's SG&A was $487M, missing the average forecast of $571.55M by -14.79%. Lastly, the company's EPS was $15.98, missing the average prediction of $16.67 by -4.13%. In terms of the last quarterly report (Sep 2023), United Therapeutics's revenue was $609.4M, beating the average analysts' forecast of $585.82M by 4.03%. The company's EBITDA was $327M, beating the average prediction of $215.4M by 51.81%. United Therapeutics's net income was $267.6M, beating the average estimation of $242.34M by 10.42%. The company's SG&A was $127.6M, missing the average forecast of $146.62M by -12.97%. Lastly, the company's EPS was $5.71, beating the average prediction of $5.1 by 11.92%